Loading...
XHEL
BIOBV
Market cap63mUSD
Dec 04, Last price  
3.58EUR
1D
-0.56%
1Q
28.32%
Jan 2017
-40.83%
Name

Biohit Oyj

Chart & Performance

D1W1MN
XHEL:BIOBV chart
P/E
20.90
P/S
3.80
EPS
0.17
Div Yield, %
Shrs. gr., 5y
0.28%
Rev. gr., 5y
7.30%
Revenues
14m
+9.36%
28,660,00031,408,00032,751,00034,805,00035,366,00040,044,00039,922,0002,048,0003,452,0004,363,0006,051,0008,195,0008,979,0009,931,00010,052,0007,123,0009,361,00010,951,00013,076,00014,300,000
Net income
3m
+40.46%
-226,000-839,000-1,502,000897,000387,00061,00037,710,000-3,656,000-5,917,000-1,161,000-2,917,000-3,295,0006,139,000-2,143,000-1,416,000-3,312,000-1,500,000601,0001,851,0002,600,000
CFO
600k
-33.48%
605,000100,0001,040,0001,188,0002,796,0001,961,0004,957,000-8,890,000-4,443,000-3,435,000-3,147,000-2,457,000-943,000-93,00083,000-25,000-444,0001,848,000902,000600,000
Dividend
Apr 15, 20140.7234 EUR/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Biohit Oyj, a biotechnology company, produces diagnostic tests and analysis systems for use in research institutions and healthcare industries worldwide. The company's diagnostic tests product range includes the GastroPanel test for diagnosing diseases of the stomach and associated risks; Biohit Active B12, a test for measuring the levels of active vitamin B12; Biohit Total, an indicator of vitamin D status; Biohit Calprotectin, a test for measuring human calprotectin; Helicobacter Pylori Quick Test and Helicobacter Pylori UFT300 Quick Test, a test methods to detect H. pylori infection from a biopsy sample during gastroscopy; ColonView Quick Test, a test for detection of fecal occult blood; Lactose Intolerance Quick Test; Celiac Disease Quick Test; and The GA-map Dysbiosis test, a gut microbiota DNA analysis tool. It also provides monoclonal antibodies for use in cellular pathology, neurobiology, oncology, and human gastric biomarkers research. In addition, the company offers acetaldehyde binding products, such as Acetium capsules that are intended for persons with a low-acid or anacidic stomach; and Acetium lozenges, which removes acetaldehyde in smoker's saliva. Further, it provides microplate readers and strip washers, quick test readers, and ThunderBolt, an automated immunoassay analyzer; and products that bind carcinogenic acetaldehyde into harmless compounds, monoclonal antibodies, and service laboratory services. The company was founded in 1988 and is headquartered in Helsinki, Finland.
IPO date
Jun 18, 1999
Employees
42
Domiciled in
FI
Incorporated in
FI

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT